- Global Pharma News & Resources

LIVE NEWS: CPHI North America

CDMO Insights at CPHI North America



‘Don’t be left short-changed post approval – plan in change orders early for accelerated pathways’


A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study.


In a keynote session at CPHI North America, Stephanie Gaulding, Executive Director of Regulatory Compliance at Pharmatech Associates, calls for innovators to, look closely at the frameworks they agree to, and work with an experienced consultant to mitigate for future challenges as products progress through clinical phases.


The drug pipeline has an increasing number of orphan and rare disease indications within it that have smaller batch volumes and accelerated pathways – which, together, means both innovator and CDMO have a greatly reduced time to work on optimal pathways. Gaulding states that preparation for this post approval work starts before signing with a CDMO, as it is this framework that will be invaluable in guiding future improvements.


“With a compressed timeline it’s very likely that further refinement will be needed post approval, but innovators must accept that as part of the strategy, and potentially conduct parallel programmes in later development – one for approval and one for post-approval process improvements. What is essential for this to run smoothly is having a good communication and governance framework in place so that the drug sponsor and the outsourcing partner are aware of what these issues are, and what the plan is for post approval remedial action,” said Gaulding.


The aim of the planning process is to ensure that any future change order can be fulfilled in the shortest timeframe possible – ideally taking just 30-45 days – and one approach to mitigate risk according to Gaulding is to concentrate on one or two markets initially rather than embarking on a multi-market entry model.


“You want to plan for change and minimise future complexity. So, if you've got accelerated pathways in multiple markets, and they classify a single post-approval change differently, then that’s going to make the situation more challenging to execute post approval. Nothing is insurmountable if you plan it sequentially, but the innovator needs to have detailed plans in place often for as long as one year post approval to map out the manufacturing improvements to get a fully optimised process - whether it's for improving yield or improving impurity profiles or reducing cycle time” said Gaulding.


When questions arise, the drug sponsor has to be able to work with their partner to get the data quickly to address any regulator query, so setting the framework up and having it in-built into agreements is vital.


CPHI North America, the ONLY end-to-end pharma event in the Americas, welcomed thousands of attendees andhundreds of companies to the Pennsylvania Convention Center this week (May 17-19, 2022). Additionally, as a SMART event, the online learning and networking will run throughout May (9-27), with on demand sessions available.






Notes to editors


About CPHI

CPHI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPHI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPHI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; and Finished Dosage Formulation for every aspect of the finished dosage supply chain.  CPHI provides an online buyer and supplier directory at


For more information visit


About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

For more information, please visit

CPhI Japan (20-22 April, 2022 at the Big Sight Exhibition Centre – Tokyo, Japan); CPhI North America (17-19 May, 2022 at Pennsylvania Convention Center, United States), Pharmapack Europe (18-19 May 2022 at Paris Expo, Porte de Versailles - Hall 7.2, Paris); CPhI & P-MEC China (21-23 June, 2021 at SNIEC – Shanghai, China); CPhI South East Asia (19-21 Oct  2022 at IMPACT, Thailand);  CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (01-03 November 2022 at Messe Frankfurt, Frankfurt); CPhI & P-MEC India (29 November – 1st December 2022 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India) 


For media enquiries, please contact:

Alex Heeley or Nidhi Narain

De Facto Communications

T: +44 (0) 203 735 8165

E: /




Editor Details

Last Updated: 19-May-2022